Livial (tibolone) / Organon - LARVOL DELTA

Comparative Effectiveness of Tibolone and Combined Hormone Therapy in Relieving Menopausal Insomnia. (PubMed, Womens Health Rep (New Rochelle)) - "The study suggests that tibolone and combined HT improved sleep to a similar extent after adjustment. Further comprehensive research is necessary to corroborate these observations."

HEOR • Journal • CNS Disorders • Insomnia • Sleep Disorder

Proposal of Chemical Inhibitors That Compete with the Binding of RNA Polymerase II Subunits to Essential GTPases GPN Npa3 and Gpn1. (PubMed, ACS Omega) - "Our analysis identified potential inhibitors, including atovaquone for both Npa3 and Gpn1 (docking scores: -14.4 and -13.5 kcal/mol, respectively) and tibolone for Npa3 (-13.6 kcal/mol), following flexible docking optimization. Additionally, our docking models suggest key residues in Npa3 such as F143 and W179, which may be critical for recognizing RNA polymerase II subunits and drug-like molecules. These findings can be further explored through biochemical and mutagenesis studies to assess their roles in RNA polymerase II recognition."

Journal

The Impact of Menopausal Hormone Therapy on Productivity and Health Care Utilization in Women: A Finnish Claims Database Study (ISPOR-EU 2025) - "During the first year, estrogen-progestogen was initiated by 60,7%, estrogen by 37,5% and tibolone by 1.8%... The study cohort includes nearly all women aged 40-70 years in Finland, enabling nationwide analysis of the effect of MHT on healthcare use and productivity. Clinicians and payors should consider the impact of menopausal symptoms on a woman's personal and professional life when evaluating the use of MHT."

Claims database • Clinical • HEOR

A high-performance adaptive fusion network for face anti-spoofing detection. (PubMed, Sci Rep) - "Finally, through adversarial training of domain discriminators, dual alignment of multi-source domain features and categories is achieved, effectively alleviating the problem of cross-domain data distribution differences. A large number of training and test results conducted on the four benchmark datasets of OULU-NPU, MSU-MFSD, CASIA-FASD and ReReplay Attack show that the performance of the proposed method is significantly better than that of the existing algorithms, providing a more innovative technical path for cross-domain face liviality detection."

Journal

The effect of Tibolone treatment on depression, anxiety and mood in women: a meta-analysis and systematic review of randomized controlled trials. (PubMed, Arch Womens Ment Health) - "Tibolone significantly improved depressive symptoms in women, with non-significant trends in anxiety and mood. However, due to high heterogeneity, risk of bias in some studies, and limited number of trials for anxiety and mood outcomes, findings should be interpreted with caution."

Journal • Retrospective data • Review • CNS Disorders • Depression • Mood Disorders • Psychiatry

EFFECTS OF TIBOLONE ON MUSCLE STRENGTH AND BODY COMPOSITION IN EARLY POSTMENOPAUSAL KOREAN WOMEN: A PROSPECTIVE COHORT STUDY (FIGO 2025) - "Tibolone therapy may increase lean and skeletal muscle mass in early postmenopausal women, although changes in muscle strength were not evident. While within-group analysis showed significant gains in lean mass, between-group comparisons did not reach statistical significance. These findings suggest a potential benefit of tibolone on body composition that warrants further investigation in larger cohorts."

Clinical

Tibolone Improves Motor Recovery and Regulates Neuroinflammation and Gliosis in a Model of Traumatic Spinal Cord Injury. (PubMed, Int J Mol Sci) - "Our findings showed that Tib regulated pro- and anti-inflammatory cytokine levels at 3 h and 3, 7, and 14 days post-SCI. Furthermore, Tib administered orally for 15 days reduced gliosis markers and favored tissue preservation and motor function recovery after SCI."

Journal • CNS Disorders • Inflammation • Orthopedics • GFAP

Cardiovascular Risk Associated with Tibolone Use in Postmenopausal Women. (PubMed, J Menopausal Med) - No abstract available

Journal • Cardiovascular

Corneal enzymatic digestion resistance in the presence of oestradiol and oestradiol plus selective tissue oestrogenic activity regulators (STEAR). (PubMed, BMJ Open Ophthalmol) - "Oestradiol significantly reduces corneal enzymatic digestion resistance. When combined with the STEAR, tibolone, there is a further decrease in stromal enzymatic digestion resistance. These results suggest that high oestradiol levels could have a significant impact on corneal conditions characterised by elevated collagenase activity, such as corneal ectasias (eg, keratoconus) and infectious keratitis. Importantly, the employment of STEAR therapy, such as tibolone, may amplify the effects of oestradiol."

Journal • Keratitis • Ocular Infections • Ocular Inflammation • Ophthalmology • ER

Sex-specific gonadal status determines prefrontal cortex proteome response to tibolone. (PubMed, Biomed Pharmacother) - "These results provide novel insights into the critical window hypothesis of hormone therapy, demonstrating that the underlying neurosteroid environment alters hormone therapy efficacy. Our findings suggest that optimal neuroprotective strategies will require sex-specific and timing-specific approaches, establishing a molecular framework for precision hormone therapy in neurodegeneration."

Journal • CNS Disorders

Treatment patterns of menopausal hormone therapy in South Korea: a nationwide cohort study. (PubMed, Climacteric) - "MHT was classified into three classes including estrogen therapy (ET), estrogen plus progestogen therapy (EPT) and tibolone, with routes of administration categorized as systemic (oral, transdermal) and local (transvaginal)...Systemic MHT was discontinued after an average of 13.2 months, while local MHT was discontinued after 2.4 months. Despite guidelines recommending MHT for treating menopausal symptoms, many women remain untreated and continued MHT for an average of only 1 year."

Journal

Menopausal Hormone Therapy and the Risk of Stroke: A Nationwide Cohort Study. (PubMed, Yonsei Med J) - "Women currently receiving MHT without underlying cardiovascular disease exhibited an increased risk of ischemic stroke, particularly those treated with E-only MHT or tibolone. However, this increased risk returned to baseline after discontinuing MHT, indicating that past use of MHT was not associated with an increased risk of ischemic stroke."

Journal • Retrospective data • Cardiovascular • Coronary Artery Disease • Heart Failure • Ischemic stroke

Acute administration of tibolone reduces oxidative stress and inflammation in a rat model of traumatic spinal cord injury. (PubMed, Neurol Res) - "TIB demonstrated a protective effect by decreasing OS and inflammation after SCI, suggesting an estrogenic effect of this STEAR. However, further studies should be conducted to elucidate the exact mechanism by which TIB exerts neuroprotection after SCI."

Journal • Preclinical • CNS Disorders • Inflammation • Orthopedics • IL1B • IL6 • TNFA

Gonadotropin-releasing hormone (GnRH) analogues for premenstrual syndrome (PMS). (PubMed, Cochrane Database Syst Rev) - "This review found that GnRH agonists without add-back improved global symptoms of premenstrual syndrome. However, the induced menopausal side effects and potential complications preclude long-term use. We found insufficient evidence to suggest that side effects can be reduced by 'add-back' without decreasing the global efficacy of GnRH agonists. Further RCTs of GnRH agonists with add-back and long-term follow-up are therefore needed to provide firm conclusions about long-term use. Until data are available to confirm or refute the safety of this combination, GnRH agonists with or without add-back can be administered to provide a short-term break from PMS symptoms. Future studies should attempt to assess the risk of osteoporosis."

Clinical • Journal • Review • CNS Disorders • Depression • Gynecology • Mental Retardation • Osteoporosis • Psychiatry • Rheumatology

Analysis of Menopausal Hormone Therapy to Chinese Patients with Menopausal Syndrome: A Real-World Retrospective Study from Chinese Hospitals. (PubMed, Drug Des Devel Ther) - "The estradiol/estradiol dydrogesterone and tibolone were the main sex hormone drugs that were used to treat MPS. The state's abolition of the drug price addition policy and the organization of centralized drug procurement in some areas had alleviated the financial burdens on patients to a certain extent."

Journal • Real-world evidence • Retrospective data

Beyond hormones: 3PM approach to vaginal microbiota dynamics in postmenopausal women. (PubMed, EPMA J) - "The analysis evaluated microbiota-based risk stratification strategies for vaginal dysbiosis and demonstrated the effectiveness of both hormonal interventions (systemic/local estrogen, tibolone, ospemifene) and non-hormonal alternatives (probiotics, energy-based devices, pessary) in normalizing microbiota composition and improving vaginal health. Developing standardized yet personalized protocols to restore a balanced vaginal microbiome could help alleviate menopause-related symptoms. Advancing microbiota-based personalized therapeutic approaches is crucial to enhancing the quality of life for postmenopausal women through targeted and individualized vaginal health management."

Journal • Review • Endocrine Disorders • Women's Health

Cardiovascular outcomes of menopause hormone therapy initiated in women aged ≥60 years or ≥10 years post-menopause: A systematic review of the literature. (PubMed, Post Reprod Health) - "Non-WHI studies showed an elevated stroke risk with tibolone and higher doses of combined MHT, but no cardiovascular complications were observed with low doses.ConclusionThe increased risk of cardiovascular events in our target population is not statistically significant. There is a lack of high-quality evidence to suggest an increased risk of adverse cardiovascular outcomes in healthy women who initiate MHT at age ≥60 years or ≥10 years post-menopause."

Journal • Review • Cardiovascular • Women's Health

Combining hormone replacement therapy and adjuvant treatment for a patient with resistant prolactinoma: a new clinical strategy (ESPE-ESE 2025) - "We administered cabergoline starting at 0.5 mg per week...In 2023–2024, with bromocriptine (5 mg/day) and tamoxifen (20 mg/day), PRL remained within the normal range... Tibolone, unlike traditional HRT, selectively activates estrogen receptors, minimizing prolactin secretion and tumor risk. This makes it a safer option for menopausal women with well-controlled prolactinomas. Conclusions : HRT helps manage vasomotor symptoms and prevent osteoporosis, but estrogen can stimulate tumor growth."

Clinical • Endocrine Cancer • Fatigue • Gynecology • Oncology • Osteoporosis • Pain • Pituitary Gland Carcinoma • Rheumatology • ER • PRL

Cardiovascular disease and female sexual health across the life span: a bidirectional link. (PubMed, Maturitas) - "Hormonal treatment for sexual dysfunction in women with cardiovascular risk factors is discussed, concerning menopausal hormone therapy, tibolone, selective estrogen receptor modulators, vaginal estrogen, prasterone and testosterone therapy...However, effectively addressing the challenges of aging and further highlighting the positive impact of sexual activity on cardiac health in selected female populations could significantly enhance life motivation and promote a healthy lifestyle during this stage. The present review elucidates the bidirectional relationship between CVD and female sexual function."

Journal • Review • Cardiovascular • Coronary Artery Disease • Dyslipidemia • Heart Failure • Hypertension • Metabolic Disorders • Myocardial Infarction • Pain • Sexual Disorders

The Effect of Tibolone on Body Weight, Body Fat, and Metabolic Components (ECO 2025) - No abstract available

Late-breaking abstract

Differential cardiovascular risks of menopausal hormone therapy: insights from a Korean cohort. (PubMed, Eur J Endocrinol) - No abstract available

Journal • Cardiovascular

Association between duration, initiation time, routes, and formulations of menopausal hormone therapy use and Alzheimer disease in women: A systematic review and meta-analysis. (PubMed, J Pharmacol Exp Ther) - "Tibolone increased AD risk (cohort, RR = 1.04, 95% CI: 1.01-1.07; case-control, OR = 1.07, 95% CI: 1.01-1.14)...MHT lowered AD risk in apolipoprotein E genotype 4 allele carriers, individuals with depression, and Americans. MHT regimens should be highly personalized."

Journal • Retrospective data • Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Dementia • Depression • Psychiatry • APOE

Study on the efficacy of different MHT protocols in intervening with cognitive function in perimenopausal and postmenopausal women with sleep disorder based on fNIRS detection (ChiCTR) - P=N/A | N=90 | Not yet recruiting | Sponsor: Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine; Shanghai Sixth People's Hospital Affiliated to Shangh

New trial • CNS Disorders • Sleep Disorder

Relation between pelvic organ prolapse and menopausal hormone therapy: nationwide cohort study. (PubMed, Obstet Gynecol Sci) - "After menopause, tibolone and CEPM were associated with a reduced POP risk compared with non-MHT. Other oral MHT and transdermal estrogen were not associated with the risk of POP."

Journal

Update of the impact of menopausal hormone therapy on breast cancer risk. (PubMed, Eur J Cancer) - "Despite possible changes towards safer MHT prescribing, our data collected largely in early millennium show at least as large BC risk elevations in MHT users as seen in older studies."

Journal • Breast Cancer • Oncology • Solid Tumor